Home » Topics » BioWorld Science

BioWorld Science
RSS

Akeso completes phase I trial of AK-117 and gains clearance for phase Ib/II trial in AML

July 13, 2021

High annexin-2 levels worsen lung injury in patients with COVID-19

July 13, 2021

Cellectar collaborates with LegoChemBio on first-in-class phospholipid drug conjugates

July 13, 2021

FDA clears Tevogen Bio's IND application for TVGN-489 for COVID-19

July 13, 2021

Safety and immunogenicity of BNT-162b1 confirmed in phase I study in Chinese adults

July 13, 2021

Uproleselan studied with venetoclax and azacitidine for older or unfit patients with AML

July 13, 2021

Vaccibody and Adaptive Biotechnologies sign license agreement on SARS-CoV-2 T-cell epitopes

July 13, 2021

Patients dosed in phase I/II trial of topical RECCE-327 for infected burn wounds

July 13, 2021

Immunic presents new preclinical and clinical data for IMU-935

July 13, 2021

Qixleef phase II protocol modifications approved

July 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Sumitomo’s DSP-3456 exerts antidepressant-like effects
BioWorld Science
About one-third of patients with major depressive disorder (MDD) are treatment resistant. Ketamine is very effective in treatment-resistant depression, but it is...